Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (328)	1/11/2001 3:44:05 PM
From: nigel bates	Respond to of 415

The presentation's available over the net. Sounded pretty good to me, but I'd be very interested if someone was actually there for the Q&A. Still undervalued (possibly considerably so) - IMO, FWIW & all usual disclaimers. Can't think why it wasn't one of my picks for this year's contest (g). nig

To: tuck who wrote (328)	1/12/2001 2:40:37 PM
From: nigel bates	Respond to of 415

Some of the highlights - New J&J collaboration will give them sufficient cash for the next 2 years... This year, expect P11 with lead parenteral cephalosporin, & P1 with second compound, plus clinical development of a novel oral ceph. compound (all J&J partnered).... On efflux pump inhibitors, expect clinical dev. cand. for the Daichi Pseudonomas compound, & announcement of preclinical candidate for the MCDE owned antifungal Azole potentiator. Also milestone to be obtained from Schering re animal health... Microbial Genomics - expect announcement of MCDE owned preclinical candidate (MC 305-904, broad spec anti-fungal), and animal health milestone from Pfizer. Emphasized discovery of 350 "essential" microbial gene targets, on about 100 of which they have filed for patents. Made big deal of announcing first antimicrobial dev. cand. resulting from genomics effort anywhere, but didn't MLNM just announce something ? Sounded upbeat to me (FWIW), with no desperation over cash evident. Was VERY positive about the platform potential of the EPI (efflux pump inhib.) programme. 29% ownership of Iconix. Awaiting more knowledgeable commentary... nig